LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday it has been granted a key patent covering its antibiotic ridinilazole for the treatment of Clostridium difficile infection by the European Patent Office.
The patent is now in force in over thirty European states, and the company has previously secured patent protection for the antibiotic in the US, Australia, New Zealand, Japan, Russia and China amongst other territories.
"The robust patent portfolio for ridinilazole, together with the strong phase 2 clinical data showing statistical superiority over vancomycin, the current standard of care, further strengthens the potentialcommercial value of this novel product candidate in the treatment of CDI," Chief Executive Glyn Edwards said in a statement.
Shares in Summit Therapeutics were down 1.6% at 127.00 pence Tuesday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
